Assertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027

Assertio Holdings (ASRT) has completed its merger with Zydus Lifesciences, marking a fundamental structural change to the company's capital and operational composition. The transaction, originally announced in May 2026, represents a cross-border combination integrating a U.S.-listed pharmaceutical entity with an India-based global health-care manufacturer. This is a known, previously-disclosed event that is now at financial completion milestone.

The merger triggers a make-whole provision on Assertio's outstanding 6.50% Convertible Senior Notes due 2027, a material covenant that obligates the combined entity to compensate holders for the fundamental change event. This mechanism protects debt investors against dilution or adverse capital structure shifts post-merger. The debt impact is predetermined and non-discretionary, reducing headline uncertainty for fixed-income holders of these convertible instruments.

For equity holders, the post-merger entity inherits dual pharmaceutical exposure—U.S. commercial infrastructure from Assertio combined with Zydus' emerging-market manufacturing footprint and generic/specialty drug portfolio. The neutral sentiment reflects that the deal completion was consensus-expected; market reaction will depend on near-term execution commentary, debt refinance terms, and synergy realization, not the closing event itself.

Sector implication: Health Care M&A and pharmaceutical consolidation remain active themes, but this deal's completion carries limited broad-index sensitivity. Convertible debt holders face known obligations; equity positions depend on post-merger operational and financial performance disclosure in coming quarters.